# Status

- Updated: 2026-09-03 (Asia/Taipei)
- Current Wave: `3 SYNTHESIS (Traditional Chinese brief + 10 QA)`
- Current Gate: `Gate 2 = READY_WITH_PENDING_ITEMS` (Decision 2026-09-03-13)

## Completed

- Runbook reviewed.
- Target Mac mini/Tailscale identity verified.
- Claude Code authentication verified.
- Public GitHub output repository verified empty at start.
- Research Charter, ownership, source policy, and sponsor-bias guardrail initialized.
- Existing global MCP names inventoried; no credential copied into the repository.
- `academic-research-agents` implementation inspected and classified as architecture-only because core literature/PDF methods contain placeholders.
- Cross-session health check PASSED: all four persistent peers (`dpnp-source-provenance`, `dpnp-guideline-diagnosis`, `dpnp-trials-comparative`, `dpnp-pregabalin-safety`) located via `ListAgents` and confirmed READY. See `90_CROSS-SESSION-LOG/2026-09-03_STARTUP.md`.
- Wave 1 dispatched to and completed by `dpnp-source-provenance`: both MedNote pages captured (`10_SOURCES/MEDNOTE_CAPTURE.md`), source/search register built (`10_SOURCES/SOURCE_REGISTER.md`) covering ADA 2026 Ch.12, AAN 2022 update, 4 trial/SR-MA leads, Toronto Consensus lead; full-text ledger opened (`10_SOURCES/FULLTEXT_LEDGER.md`); `02_SOURCE-INVENTORY.md` updated with a preserved "not yet accepted" framing. No PDFs downloaded/parsed, no Sci-Hub/paywall bypass, no credentials committed.
- Gate 1 declared `READY_WITH_PENDING_ITEMS` (Decision 2026-09-03-05) — sufficient lead coverage to unblock Wave 2 deep verification; real gaps remain (see Open Questions).
- Wave 2 dispatched to `dpnp-guideline-diagnosis`, `dpnp-trials-comparative`, `dpnp-pregabalin-safety`.

## In progress

- `dpnp-source-provenance`: closing remaining gaps in its own scope — Taiwan TFDA and FDA/DailyMed Pregabalin label discovery, ADA Ch.12 DOI confirmation.
- `dpnp-guideline-diagnosis`: open and verify ADA 2026 Ch.12, AAN 2022 update, and Toronto Consensus at their primary records with exact quotations/locators.
- `dpnp-pregabalin-safety`: independently search for the Taiwan/FDA Pregabalin label rather than wait on source-provenance; verify labeling and safety evidence.

## Completed (Wave 2 — all three specialists reported and accepted)

- `dpnp-trials-comparative`: Wave 2 evidence table complete (`20_EVIDENCE/trials-comparative/01_EVIDENCE-TABLE.md`) — T1 Freeman 2008, T2 Frontiers 2026 combo SR-MA, T3 Soliman/NeuPSIG 2025, T4 Mallick-Searle 2024 (narrative review), T5 COMBO-DN, T6 OPTION-DM all `ACCESS_VERIFIED` at primary record. Key counter-bias findings recorded (Decision 2026-09-03-06): α2δ-ligand class NNT ranks numerically worst of the three first-line classes per Soliman/NeuPSIG 2025; COMBO-DN found no significant combination-vs-monotherapy superiority; OPTION-DM found no pregabalin-pathway superiority over amitriptyline/duloxetine pathways.
- `dpnp-guideline-diagnosis`: Wave 2 claim table complete (`20_EVIDENCE/guidelines-diagnosis/01_CLAIM-TABLE.md`) — ADA 2026 Ch.12, AAN 2022 (+ AAN 2011 confirmed retired), Toronto Consensus 2010, and Atmaca 2024 (EXPERT INTERPRETATION, not a formal successor consensus) all `ACCESS_VERIFIED`. Independently corroborating counter-bias finding recorded (Decision 2026-09-03-08): current operative guidelines grade the drug class, not pregabalin specifically; only the retired 2011 AAN guideline gave pregabalin a drug-specific Level A.
- `dpnp-pregabalin-safety`: Wave 2 label verification complete (Decision 2026-09-03-09) — FDA label (Rev. 04/2025) and TFDA-stamped Taiwan insert both `ACCESS_VERIFIED`, numerically concordant on dosing/renal-adjustment/AE tables. All dispatched safety topics covered with locators. Two open items flagged, not guessed: Taiwan controlled-drug schedule unresolved; HLA-B*1502 mention identified as a likely template artifact and excluded from use.
- Wave 2 dispatch (task #3) is now complete for all three specialists.

## Completed (Challenge Round / Gate 2)

- All three Wave 2 specialists completed the adversarial challenge round. `dpnp-trials-comparative` produced four synthesis-phrasing guardrails against both overselling and over-correcting (Decision 2026-09-03-10), plus a targeted falls/fracture search (population-mismatched leads, routed to pregabalin-safety). `dpnp-guideline-diagnosis` found and transparently corrected a real extraction-tool locator error (Rec-number mislabeling, no clinical content changed — Decision 2026-09-03-11). `dpnp-pregabalin-safety` produced anti-downplaying/anti-overstating guardrail sentences plus a compounded-risk callout and a documentation-depth-asymmetry guardrail (Decision 2026-09-03-12).
- **Gate 2 declared `READY_WITH_PENDING_ITEMS`** (Decision 2026-09-03-13). Wave 3 (Director synthesis) now authorized to begin.

## Pending gates

- Gate 1: `READY_WITH_PENDING_ITEMS` (partial — see above).
- Gate 2: `READY_WITH_PENDING_ITEMS` (Decision 2026-09-03-13).
- Gate 3: Traditional Chinese synthesis and exactly 10 QA internally consistent — in progress.
- Final Gate: independent read-only QA + PI requirement (Decision 2026-09-03-07: at least one lawful full-text PDF downloaded and LlamaParse-parsed) must be satisfied. As of this update: FDA label PDF lawfully downloaded (SHA-256 logged), but LlamaParse failed 3 consecutive times (tool-specific timeout, not a policy block); ADA Ch.12 PMC PDF correctly declined due to a text/data-mining license restriction. Not yet satisfied — retry/fallback in progress with `dpnp-source-provenance`.

## Blockers

- None hard-blocking; several `NEEDS_SOURCE`/`NEEDS_EVIDENCE`/`NEEDS_FULLTEXT` items open (see `04_OPEN-QUESTIONS.md`). No claim may cite MEDNOTE-002's numeric figures (NNT/NNH/discontinuation) until independently sourced to a primary study. PI's lawful-PDF+LlamaParse requirement (Decision 2026-09-03-07) is dispatched to `dpnp-source-provenance`, outcome not yet reported.
